|
G |
Adra1a |
adrenoceptor alpha 1A |
multiple interactions |
ISO |
phenethylamine binds to and results in decreased activity of ADRA1A protein |
CTD |
PMID:20217639 |
|
NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500
|
|
G |
Adra2a |
adrenoceptor alpha 2A |
affects binding |
ISO |
phenethylamine binds to ADRA2A protein |
CTD |
PMID:20217639 |
|
NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365
|
|
G |
Adra2c |
adrenoceptor alpha 2C |
affects binding |
ISO |
phenethylamine binds to ADRA2C protein |
CTD |
PMID:20217639 |
|
NCBI chr14:75,470,884...75,472,846
Ensembl chr14:75,471,143...75,472,846
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
[NAT2 protein results in increased susceptibility to phenethylamine] which results in increased expression of H2AX protein |
CTD |
PMID:36138126 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Maob |
monoamine oxidase B |
multiple interactions |
ISO |
Phenylpropanolamine inhibits the reaction [MAOB protein results in increased degradation of phenethylamine] |
CTD |
PMID:3961266 |
|
NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003
|
|
G |
Nat2 |
N-acetyltransferase 2 |
increases acetylation increases response to substance multiple interactions |
ISO |
NAT2 protein results in increased acetylation of phenethylamine NAT2 protein results in increased susceptibility to phenethylamine [NAT2 protein results in increased susceptibility to phenethylamine] which results in increased expression of H2AX protein |
CTD |
PMID:36138126 |
|
NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520
|
|
G |
Slc18a1 |
solute carrier family 18 member A1 |
multiple interactions |
ISO |
phenethylamine inhibits the reaction [SLC18A1 protein results in increased uptake of Serotonin] |
CTD |
PMID:8245983 |
|
NCBI chr16:20,653,268...20,687,051
Ensembl chr16:20,653,508...20,687,051
|
|
G |
Slc6a2 |
solute carrier family 6 member 2 |
multiple interactions |
ISO |
SLC6A2 protein promotes the reaction [phenethylamine results in increased activity of TAAR1 protein] |
CTD |
PMID:17234900 |
|
NCBI chr19:14,010,292...14,055,317
Ensembl chr19:14,010,386...14,050,357
|
|
G |
Slc6a3 |
solute carrier family 6 member 3 |
multiple interactions increases transport |
ISO |
Cocaine inhibits the reaction [SLC6A3 protein results in increased transport of phenethylamine]; SLC6A3 protein promotes the reaction [phenethylamine results in increased activity of TAAR1 protein] |
CTD |
PMID:15764732 PMID:17234900 |
|
NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413
|
|
G |
Slc6a4 |
solute carrier family 6 member 4 |
multiple interactions |
ISO |
SLC6A4 protein promotes the reaction [phenethylamine results in increased activity of TAAR1 protein] |
CTD |
PMID:17234900 |
|
NCBI chr10:61,824,208...61,858,924
Ensembl chr10:61,826,123...61,858,384
|
|
G |
Taar1 |
trace-amine-associated receptor 1 |
multiple interactions increases activity |
ISO |
[phenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; SLC6A2 protein promotes the reaction [phenethylamine results in increased activity of TAAR1 protein]; SLC6A3 protein promotes the reaction [phenethylamine results in increased activity of TAAR1 protein]; SLC6A4 protein promotes the reaction [phenethylamine results in increased activity of TAAR1 protein] |
CTD |
PMID:17234900 PMID:19725810 |
|
NCBI chr 1:21,517,742...21,518,740
Ensembl chr 1:21,517,258...21,532,084
|
|
|
G |
Taar1 |
trace-amine-associated receptor 1 |
increases activity multiple interactions |
ISO |
O-methyltyramine results in increased activity of TAAR1 protein [O-methyltyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:19725810 |
|
NCBI chr 1:21,517,742...21,518,740
Ensembl chr 1:21,517,258...21,532,084
|
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases expression |
ISO |
4-phenylbutylamine results in increased expression of ABCC4 mRNA; 4-phenylbutylamine results in increased expression of ABCC4 protein |
CTD |
PMID:20395535 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
multiple interactions |
EXP |
4-phenylbutylamine inhibits the reaction [4-hydroxy-2-nonenal results in increased expression of BBC3 mRNA] |
CTD |
PMID:24291486 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
4-phenylbutylamine promotes the reaction [Zearalenone results in increased expression of DDIT3 protein] |
CTD |
PMID:30394307 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Herpud1 |
homocysteine inducible ER protein with ubiquitin like domain 1 |
multiple interactions |
ISO |
4-phenylbutylamine promotes the reaction [Zearalenone results in increased expression of HERPUD1 protein] |
CTD |
PMID:30394307 |
|
NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
4-phenylbutylamine inhibits the reaction [4-hydroxy-2-nonenal results in increased expression of HMOX1 mRNA] |
CTD |
PMID:24291486 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
4-phenylbutylamine promotes the reaction [Zearalenone results in increased expression of HSPA5 protein] |
CTD |
PMID:30394307 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
multiple interactions |
EXP |
4-phenylbutylamine inhibits the reaction [4-hydroxy-2-nonenal results in increased expression of TRIB3 mRNA] |
CTD |
PMID:24291486 |
|
NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
benzylamine binds to and results in increased activity of AHR protein |
CTD |
PMID:11790108 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases secretion |
ISO |
p-Methoxy-N-methylphenethylamine results in increased secretion of CCL2 protein |
CTD |
PMID:34826398 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Gusb |
glucuronidase, beta |
increases secretion |
EXP |
p-Methoxy-N-methylphenethylamine results in increased secretion of GUSB protein |
CTD |
PMID:9545557 |
|
NCBI chr12:26,701,188...26,714,718
Ensembl chr12:26,697,951...26,726,905
|
|
G |
Hexa |
hexosaminidase subunit alpha |
increases secretion multiple interactions |
ISO |
p-Methoxy-N-methylphenethylamine results in increased secretion of HEXA protein Apigenin inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased secretion of HEXA protein] |
CTD |
PMID:36350155 |
|
NCBI chr 8:59,936,526...59,961,654
Ensembl chr 8:59,936,660...59,962,013
|
|
G |
Hexb |
hexosaminidase subunit beta |
increases secretion |
ISO |
p-Methoxy-N-methylphenethylamine results in increased secretion of HEXB protein |
CTD |
PMID:34774977 |
|
NCBI chr 2:28,483,997...28,504,165
Ensembl chr 2:28,484,012...28,504,223
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
increases activity |
EXP |
p-Methoxy-N-methylphenethylamine results in increased activity of HTR1A protein |
CTD |
PMID:16415902 |
|
NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
affects response to substance |
ISO |
KIT protein affects the susceptibility to p-Methoxy-N-methylphenethylamine |
CTD |
PMID:32871113 |
|
NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652
|
|
G |
Kng1 |
kininogen 1 |
decreases activity |
ISO |
p-Methoxy-N-methylphenethylamine results in decreased activity of KNG1 protein |
CTD |
PMID:1371395 |
|
NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555
|
|
G |
Lck |
LCK proto-oncogene, Src family tyrosine kinase |
multiple interactions increases activity |
EXP |
atractylon inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased activity of LCK protein]; damnacanthal inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased activity of LCK protein]; pyeongwee-san extract inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased activity of LCK protein] |
CTD |
PMID:27553716 |
|
NCBI chr 5:141,888,318...141,916,945
Ensembl chr 5:141,888,326...141,903,794
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
epigallocatechin gallate inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:29402411 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
epigallocatechin gallate inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:29402411 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mrgprx2 |
MAS related GPR family member X2 |
affects response to substance |
ISO |
MRGPRX2 protein affects the susceptibility to p-Methoxy-N-methylphenethylamine |
CTD |
PMID:32871113 |
|
NCBI chr 1:98,116,192...98,135,534
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
decreases activity |
ISO |
p-Methoxy-N-methylphenethylamine results in decreased activity of NR3C1 protein |
CTD |
PMID:7887964 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Tnf |
tumor necrosis factor |
increases secretion |
ISO |
p-Methoxy-N-methylphenethylamine results in increased secretion of TNF protein |
CTD |
PMID:34826398 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tpsb2 |
tryptase beta 2 |
increases secretion |
ISO |
p-Methoxy-N-methylphenethylamine results in increased secretion of TPSB2 protein |
CTD |
PMID:34826398 |
|
NCBI chr10:14,381,779...14,383,571
Ensembl chr10:14,382,013...14,383,569
|
|
|
G |
Dek |
DEK proto-oncogene |
increases secretion |
ISO |
DEK protein results in increased secretion of dimethylamine |
CTD |
PMID:28558019 |
|
NCBI chr17:17,580,804...17,602,825
Ensembl chr17:17,580,843...17,602,808
|
|
G |
Hrh3 |
histamine receptor H3 |
multiple interactions |
ISO EXP |
dimethylamine binds to and results in decreased activity of HRH3 protein |
CTD |
PMID:17169555 |
|
NCBI chr 3:167,191,551...167,196,642
Ensembl chr 3:167,191,558...167,196,642
|
|
|
G |
Aoc3 |
amine oxidase, copper containing 3 |
decreases amination multiple interactions |
ISO |
AOC3 protein results in decreased amination of methylamine mofegiline inhibits the reaction [AOC3 protein results in decreased amination of methylamine] |
CTD |
PMID:15128865 |
|
NCBI chr10:86,272,757...86,280,702
|
|
G |
Ifnar1 |
interferon alpha and beta receptor subunit 1 |
multiple interactions |
ISO |
methylamine inhibits the reaction [Tobacco Smoke Pollution results in decreased expression of IFNAR1 protein] |
CTD |
PMID:18722370 |
|
NCBI chr11:30,725,774...30,752,227
Ensembl chr11:30,725,790...30,749,979
|
|
G |
Kcna6 |
potassium voltage-gated channel subfamily A member 6 |
affects response to substance |
ISO |
KCNA6 protein affects the susceptibility to methylamine |
CTD |
PMID:15100162 |
|
NCBI chr 4:159,542,941...159,576,189
Ensembl chr 4:159,542,615...159,576,189
|
|
G |
Snap25 |
synaptosome associated protein 25 |
multiple interactions |
ISO |
methylamine inhibits the reaction [Botulinum Toxins, Type A results in increased cleavage of SNAP25 protein] |
CTD |
PMID:11181932 |
|
NCBI chr 3:124,041,898...124,123,761
Ensembl chr 3:124,041,898...124,123,760
|
|
|
G |
Car1 |
carbonic anhydrase 1 |
decreases activity |
ISO |
Methylamines analog results in decreased activity of CA1 protein |
CTD |
PMID:29457667 |
|
NCBI chr 2:86,829,436...86,872,209
Ensembl chr 2:86,861,897...86,872,208
|
|
G |
Car2 |
carbonic anhydrase 2 |
decreases activity |
ISO |
Methylamines analog results in decreased activity of CA2 protein |
CTD |
PMID:29457667 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases secretion |
ISO |
p-Methoxy-N-methylphenethylamine results in increased secretion of CCL2 protein |
CTD |
PMID:34826398 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Gusb |
glucuronidase, beta |
increases secretion |
EXP |
p-Methoxy-N-methylphenethylamine results in increased secretion of GUSB protein |
CTD |
PMID:9545557 |
|
NCBI chr12:26,701,188...26,714,718
Ensembl chr12:26,697,951...26,726,905
|
|
G |
Hexa |
hexosaminidase subunit alpha |
multiple interactions increases secretion |
ISO |
Apigenin inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased secretion of HEXA protein] |
CTD |
PMID:36350155 |
|
NCBI chr 8:59,936,526...59,961,654
Ensembl chr 8:59,936,660...59,962,013
|
|
G |
Hexb |
hexosaminidase subunit beta |
increases secretion |
ISO |
p-Methoxy-N-methylphenethylamine results in increased secretion of HEXB protein |
CTD |
PMID:34774977 |
|
NCBI chr 2:28,483,997...28,504,165
Ensembl chr 2:28,484,012...28,504,223
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
increases activity |
EXP |
p-Methoxy-N-methylphenethylamine results in increased activity of HTR1A protein |
CTD |
PMID:16415902 |
|
NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
affects response to substance |
ISO |
KIT protein affects the susceptibility to p-Methoxy-N-methylphenethylamine |
CTD |
PMID:32871113 |
|
NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652
|
|
G |
Kng1 |
kininogen 1 |
decreases activity |
ISO |
p-Methoxy-N-methylphenethylamine results in decreased activity of KNG1 protein |
CTD |
PMID:1371395 |
|
NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555
|
|
G |
Lck |
LCK proto-oncogene, Src family tyrosine kinase |
multiple interactions increases activity |
EXP |
atractylon inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased activity of LCK protein]; damnacanthal inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased activity of LCK protein]; pyeongwee-san extract inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased activity of LCK protein] |
CTD |
PMID:27553716 |
|
NCBI chr 5:141,888,318...141,916,945
Ensembl chr 5:141,888,326...141,903,794
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
p-Methoxy-N-methylphenethylamine results in increased phosphorylation of MAPK1 protein epigallocatechin gallate inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:29402411 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
epigallocatechin gallate inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:29402411 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mrgprx2 |
MAS related GPR family member X2 |
affects response to substance |
ISO |
MRGPRX2 protein affects the susceptibility to p-Methoxy-N-methylphenethylamine |
CTD |
PMID:32871113 |
|
NCBI chr 1:98,116,192...98,135,534
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
decreases activity |
ISO |
p-Methoxy-N-methylphenethylamine results in decreased activity of NR3C1 protein |
CTD |
PMID:7887964 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Tnf |
tumor necrosis factor |
increases secretion |
ISO |
p-Methoxy-N-methylphenethylamine results in increased secretion of TNF protein |
CTD |
PMID:34826398 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tpsb2 |
tryptase beta 2 |
increases secretion |
ISO |
p-Methoxy-N-methylphenethylamine results in increased secretion of TPSB2 protein |
CTD |
PMID:34826398 |
|
NCBI chr10:14,381,779...14,383,571
Ensembl chr10:14,382,013...14,383,569
|
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
affects response to substance |
ISO |
AKT2 protein affects the susceptibility to N-(3-(aminomethyl)benzyl)acetamidine |
CTD |
PMID:21964073 |
|
NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
multiple interactions |
ISO |
[N-(3-(aminomethyl)benzyl)acetamidine results in decreased activity of NOS2 protein] inhibits the reaction [manganese chloride results in increased expression of BNIP3 protein] |
CTD |
PMID:19442826 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Cav1 |
caveolin 1 |
multiple interactions |
ISO |
N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [Oxygen deficiency results in increased expression of CAV1 protein] |
CTD |
PMID:18717816 |
|
NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A1 protein] |
CTD |
PMID:15542068 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A2 protein] |
CTD |
PMID:15542068 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions |
ISO |
N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [Phenytoin results in increased expression of CYP2B6 mRNA] |
CTD |
PMID:18206661 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [Oxidopamine results in increased expression of HMOX1 protein] |
CTD |
PMID:21397656 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein] |
CTD |
PMID:11076874 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein] |
CTD |
PMID:11076874 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Ins1 |
insulin 1 |
increases response to substance |
ISO |
N-(3-(aminomethyl)benzyl)acetamidine results in increased susceptibility to INS1 protein |
CTD |
PMID:21964073 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Itgb2 |
integrin subunit beta 2 |
multiple interactions |
ISO |
N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [ITGB2 protein results in increased activity of RAP1A protein]; N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [ITGB2 protein results in increased activity of RAP2A protein] |
CTD |
PMID:16963453 |
|
NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600
|
|
G |
Lepr |
leptin receptor |
increases response to substance |
EXP |
LEPR gene mutant form results in increased susceptibility to N-(3-(aminomethyl)benzyl)acetamidine |
CTD |
PMID:30689673 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [Indomethacin results in increased activity of MPO protein]; N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] |
CTD |
PMID:11504810 PMID:11713966 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases activity |
ISO EXP |
[N-(3-(aminomethyl)benzyl)acetamidine results in decreased activity of NOS2 protein] inhibits the reaction [fluvastatin results in increased abundance of Nitric Oxide]; N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein] [N-(3-(aminomethyl)benzyl)acetamidine results in decreased activity of NOS2 protein] which results in increased susceptibility to endothelium-dependent hyperpolarization factor; N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2]; N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [Potassium Cyanide results in increased expression of NOS2 protein] [N-(3-(aminomethyl)benzyl)acetamidine results in decreased activity of NOS2 protein] inhibits the reaction [manganese chloride results in increased chemical synthesis of Reactive Oxygen Species]; [N-(3-(aminomethyl)benzyl)acetamidine results in decreased activity of NOS2 protein] inhibits the reaction [manganese chloride results in increased expression of BNIP3 protein] |
CTD |
PMID:11076874 PMID:11134894 PMID:16461118 PMID:16933320 PMID:19442826 PMID:19951519 PMID:20035746 PMID:20497644 PMID:20549418 PMID:23061969 PMID:24964743 More...
|
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Rap1a |
RAP1A, member of RAS oncogene family |
multiple interactions |
ISO |
N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [ITGB2 protein results in increased activity of RAP1A protein] |
CTD |
PMID:16963453 |
|
NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501
|
|
G |
Rap2a |
RAP2A, member of RAS oncogene family |
multiple interactions |
ISO |
N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [ITGB2 protein results in increased activity of RAP2A protein] |
CTD |
PMID:16963453 |
|
NCBI chr15:97,596,848...97,597,338
Ensembl chr15:97,596,020...97,624,138
|
|
G |
Tfrc |
transferrin receptor |
multiple interactions |
ISO |
N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [fluvastatin results in decreased expression of TFRC protein]; N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [GGTI 298 results in decreased expression of TFRC protein] |
CTD |
PMID:24964743 |
|
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein] |
CTD |
PMID:11076874 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Hrh2 |
histamine receptor H 2 |
multiple interactions |
EXP ISO |
N-methylhistamine inhibits the reaction [tiotidine binds to HRH2 protein] N-methylhistamine binds to and results in increased activity of HRH2 protein |
CTD |
PMID:12010879 |
|
NCBI chr17:10,366,004...10,407,791
Ensembl chr17:10,368,298...10,407,631
|
|
G |
Hrh3 |
histamine receptor H3 |
affects binding multiple interactions |
ISO |
N-methylhistamine binds to HRH3 protein 3-fluoro-3-(3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl)-N-(2-methylpropyl)cyclobutanecarboxamide inhibits the reaction [N-methylhistamine binds to HRH3 protein]; N-ethyl-3-fluoro-3-(3-fluoro-4-(pyrrolidinylmethyl)phenyl)cyclobutanecarboxamide inhibits the reaction [N-methylhistamine binds to HRH3 protein] |
CTD |
PMID:21928839 |
|
NCBI chr 3:167,191,551...167,196,642
Ensembl chr 3:167,191,558...167,196,642
|
|
G |
Hrh4 |
histamine receptor H4 |
multiple interactions |
ISO |
[N-methylhistamine binds to and results in increased activity of HRH4 protein] which results in increased abundance of Calcium; N-methylhistamine binds to and results in increased activity of HRH4 protein |
CTD |
PMID:11181941 |
|
NCBI chr18:4,166,270...4,182,426
Ensembl chr18:4,166,270...4,246,345
|
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
ISO EXP |
Ranitidine binds to and results in decreased activity of ACHE protein; Ranitidine inhibits the reaction [Paraoxon results in decreased activity of ACHE protein] Ranitidine affects the reaction [Paraoxon results in decreased activity of ACHE protein] |
CTD |
PMID:15669026 PMID:15669039 PMID:16193528 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Ackr3 |
atypical chemokine receptor 3 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ACKR3 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ACKR3 mRNA]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of ACKR3 mRNA] |
CTD |
PMID:16401727 PMID:16415329 |
|
NCBI chr 9:90,799,682...90,811,246
Ensembl chr 9:90,799,686...90,811,237
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ADAMTS1 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ADAMTS1 mRNA]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of ADAMTS1 mRNA] |
CTD |
PMID:16401727 PMID:16415329 |
|
NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103
|
|
G |
Alb |
albumin |
multiple interactions |
EXP |
[Ranitidine co-treated with Diclofenac] results in decreased expression of ALB protein; Quercetin inhibits the reaction [[Ranitidine co-treated with Diclofenac] results in decreased expression of ALB protein] |
CTD |
PMID:28400101 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ALDOA mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182
|
|
G |
Amotl2 |
angiomotin like 2 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Lipopolysaccharides results in increased expression of AMOTL2 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 8:103,303,368...103,319,161
Ensembl chr 8:103,302,992...103,318,910
|
|
G |
Arhgef11 |
Rho guanine nucleotide exchange factor 11 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ARHGEF11 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 2:173,074,383...173,195,962
Ensembl chr 2:173,074,368...173,196,010
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ATF3 mRNA; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of ATF3 mRNA] |
CTD |
PMID:16401727 PMID:16415329 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atp1b1 |
ATPase Na+/K+ transporting subunit beta 1 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ATP1B1 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ATP1B1 mRNA]; Ranitidine inhibits the reaction [Lipopolysaccharides results in decreased expression of ATP1B1 mRNA] |
CTD |
PMID:16401727 PMID:16415329 |
|
NCBI chr13:76,786,580...76,807,096
Ensembl chr13:76,786,578...76,807,459
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO EXP |
Ranitidine inhibits the reaction [Rotenone results in increased expression of BAX protein] Ranitidine inhibits the reaction [Aspirin results in increased expression of BAX protein] |
CTD |
PMID:19723537 PMID:30885738 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions |
ISO |
Ranitidine binds to and results in decreased activity of BCHE protein; Ranitidine inhibits the reaction [Paraoxon results in decreased activity of BCHE protein] |
CTD |
PMID:15669026 PMID:16193528 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Rotenone results in decreased expression of BCL2 protein] |
CTD |
PMID:19723537 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of BHLHE40 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Lipopolysaccharides results in decreased expression of BMP2 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of BNIP3 mRNA |
CTD |
PMID:16401727 PMID:16415329 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of BTG2 mRNA; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of BTG2 mRNA] |
CTD |
PMID:16401727 PMID:16415329 |
|
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
increases expression |
ISO |
Ranitidine results in increased expression of CALCA protein |
CTD |
PMID:12495560 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
Ranitidine inhibits the reaction [Rotenone results in increased cleavage of and results in increased activity of CASP3 protein] Ranitidine inhibits the reaction [Aspirin results in increased expression of CASP3 mRNA]; Ranitidine inhibits the reaction [Aspirin results in increased expression of CASP3 protein]; Ranitidine inhibits the reaction [Indomethacin results in increased expression of CASP3 mRNA]; Ranitidine inhibits the reaction [Indomethacin results in increased expression of CASP3 protein] |
CTD |
PMID:19723537 PMID:28648817 PMID:29523851 PMID:30580614 PMID:30885738 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Rotenone results in increased cleavage of CASP9 protein] |
CTD |
PMID:19723537 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Indomethacin results in decreased activity of CAT protein]; Ranitidine inhibits the reaction [Indomethacin results in increased activity of CAT protein] |
CTD |
PMID:16169175 PMID:16397915 PMID:17895592 PMID:18087811 PMID:18726076 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccnl1 |
cyclin L1 |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of CCNL1 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 2:150,184,865...150,199,524
Ensembl chr 2:150,184,798...150,197,368
|
|
G |
Cd80 |
Cd80 molecule |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Histamine inhibits the reaction [Lipopolysaccharides results in increased expression of CD80 protein]] |
CTD |
PMID:12538815 |
|
NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in decreased expression of CDK6 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Crem |
cAMP responsive element modulator |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of CREM mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989
|
|
G |
Csf3 |
colony stimulating factor 3 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of CSF3 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of CSF3 mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603
|
|
G |
Ctsl |
cathepsin L |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of CTSL mRNA |
CTD |
PMID:16415329 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
decreases expression |
EXP |
Ranitidine results in decreased expression of CXCL1 protein |
CTD |
PMID:12023551 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of CXCL2 mRNA; [Ranitidine co-treated with Lipopolysaccharides] results in increased expression of CXCL2 protein; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of CXCL2 mRNA]; Heparin inhibits the reaction [Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of CXCL2 protein]]; Pentoxifylline inhibits the reaction [[Ranitidine co-treated with Lipopolysaccharides] results in increased expression of CXCL2 protein]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of CXCL2 mRNA]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of CXCL2 protein] |
CTD |
PMID:16401727 PMID:16415329 PMID:17698507 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Ddah1 |
dimethylarginine dimethylaminohydrolase 1 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Indomethacin results in decreased expression of DDAH1 mRNA] |
CTD |
PMID:29523851 |
|
NCBI chr 2:234,667,499...234,800,322
Ensembl chr 2:234,667,491...234,799,339
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of DDIT4 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of DIO3 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of DUSP1 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr10:16,680,478...16,683,275
|
|
G |
Efna1 |
ephrin A1 |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of EFNA1 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 2:174,681,676...174,689,061
Ensembl chr 2:174,681,682...174,690,866
|
|
G |
Egfl7 |
EGF-like-domain, multiple 7 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in decreased expression of EGFL7 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 3:9,404,622...9,416,879
Ensembl chr 3:9,407,520...9,416,879
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Indomethacin results in increased expression of EGFR mRNA] |
CTD |
PMID:29523851 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egln3 |
egl-9 family hypoxia-inducible factor 3 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of EGLN3 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of EGLN3 mRNA] |
CTD |
PMID:16401727 PMID:16415329 |
|
NCBI chr 6:71,650,297...71,675,766
Ensembl chr 6:71,650,297...71,675,766
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of EGR1 mRNA; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of EGR1 mRNA] |
CTD |
PMID:16401727 PMID:16415329 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Lipopolysaccharides results in decreased expression of F3 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fgf23 |
fibroblast growth factor 23 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of FGF23 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 4:159,914,267...159,923,821
Ensembl chr 4:159,914,272...159,923,821
|
|
G |
Fmo3 |
flavin containing dimethylaniline monoxygenase 3 |
affects metabolic processing |
ISO |
FMO3 protein affects the metabolism of Ranitidine |
CTD |
PMID:15286053 |
|
NCBI chr13:75,309,367...75,334,915
Ensembl chr13:75,309,374...75,328,028
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of FOS mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosl2 |
FOS like 2, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of FOSL2 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 6:24,297,898...24,319,219
Ensembl chr 6:24,300,956...24,320,034
|
|
G |
Foxq1 |
forkhead box Q1 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of FOXQ1 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr17:32,912,744...32,915,377
Ensembl chr17:32,912,744...32,915,377 Ensembl chr17:32,912,744...32,915,377
|
|
G |
Fst |
follistatin |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of FST mRNA; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of FST mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 2:46,123,260...46,130,584
Ensembl chr 2:46,123,439...46,130,571
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of GADD45A mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Gast |
gastrin |
affects expression multiple interactions |
ISO EXP |
Ranitidine affects the expression of GAST protein Ranitidine inhibits the reaction [GAST protein modified form results in increased secretion of Acids] |
CTD |
PMID:2470453 PMID:12503773 |
|
NCBI chr10:85,264,832...85,269,393
Ensembl chr10:85,264,832...85,267,496
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of GOT1 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Gzmb |
granzyme B |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of GZMB mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of GZMB mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr15:30,343,352...30,346,814
Ensembl chr15:30,173,603...30,346,814
|
|
G |
H2ac25 |
H2A clustered histone 25 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of H2A mRNA |
CTD |
PMID:16415329 |
|
NCBI chr10:43,733,702...43,735,254
Ensembl chr10:43,733,668...43,744,874
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Indomethacin results in decreased expression of HMOX1 mRNA]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 mRNA] |
CTD |
PMID:16415329 PMID:30580614 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in decreased expression of HNF4A mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320
|
|
G |
Homer1 |
homer scaffold protein 1 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of HOMER1 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 2:24,542,777...24,645,715
Ensembl chr 2:24,543,093...24,644,785
|
|
G |
Hoxa5 |
homeo box A5 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of HOXA5 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 4:81,302,341...81,306,234
Ensembl chr 4:81,302,353...81,306,234
|
|
G |
Hrh2 |
histamine receptor H 2 |
multiple interactions decreases activity |
ISO EXP |
[Ranitidine binds to and results in decreased activity of HRH2 protein] which affects the susceptibility to Metformin; Ranitidine binds to and results in decreased activity of HRH2 protein; Ranitidine inhibits the reaction [tiotidine binds to HRH2 protein] Ranitidine results in decreased activity of HRH2 protein Ranitidine binds to and results in decreased activity of HRH2 protein; Ranitidine inhibits the reaction [Dimaprit binds to and results in increased activity of HRH2 protein]; Ranitidine inhibits the reaction [Melitten results in increased activity of HRH2 protein] |
CTD |
PMID:6106871 PMID:6835285 PMID:7512805 PMID:9681472 PMID:9819373 PMID:11527950 PMID:12100006 PMID:14671421 PMID:16143415 PMID:16632449 PMID:22995146 More...
|
|
NCBI chr17:10,366,004...10,407,791
Ensembl chr17:10,368,298...10,407,631
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of HSPA1A mRNA |
CTD |
PMID:16415329 |
|
NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227
|
|
G |
Hspb8 |
heat shock protein family B (small) member 8 |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of HSPB8 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr12:40,176,405...40,205,002
Ensembl chr12:40,176,532...40,191,185
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of ICAM1 protein]]; Ranitidine inhibits the reaction [Histamine inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]] |
CTD |
PMID:11752121 PMID:12538815 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Lipopolysaccharides results in decreased expression of ID2 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400
|
|
G |
Id4 |
inhibitor of DNA binding 4 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Lipopolysaccharides results in decreased expression of ID4 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr17:16,389,387...16,391,956
Ensembl chr17:16,389,387...16,392,470
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO EXP |
Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of IFNG protein]]; Ranitidine inhibits the reaction [Histamine inhibits the reaction [Lipopolysaccharides results in increased expression of IFNG protein]] [IFNG protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Ranitidine; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of IFNG mRNA]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of IFNG protein] |
CTD |
PMID:10569698 PMID:11752121 PMID:16415329 PMID:17698507 PMID:19362101 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ifrd1 |
interferon-related developmental regulator 1 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of IFRD1 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 6:57,269,395...57,317,833
Ensembl chr 6:57,269,384...57,288,990
|
|
G |
Igsf10 |
immunoglobulin superfamily, member 10 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of IGSF10 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of IGSF10 mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr 2:143,575,710...143,605,044
Ensembl chr 2:143,576,070...143,604,773
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP ISO |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of IL10 protein] Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in decreased expression of IL10 protein]] |
CTD |
PMID:11752121 PMID:17698507 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of [IL12A protein binds to IL12B protein]]]; Ranitidine inhibits the reaction [Histamine results in decreased expression of IL12A protein] |
CTD |
PMID:9819373 PMID:11752121 |
|
NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of [IL12A protein binds to IL12B protein]]]; Ranitidine inhibits the reaction [Histamine results in decreased expression of IL12B protein] |
CTD |
PMID:9819373 PMID:11752121 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Cimetidine results in increased expression of IL18 protein]; Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in decreased expression of IL10 protein]]; Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of [IL12A protein binds to IL12B protein]]]; Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of ICAM1 protein]]; Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of IFNG protein]]; Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of TNF protein]] |
CTD |
PMID:11752121 PMID:16723495 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
EXP |
[IFNG protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Ranitidine |
CTD |
PMID:19362101 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
EXP |
Ranitidine results in increased expression of IL1B protein Pentoxifylline inhibits the reaction [Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; Ranitidine inhibits the reaction [Capsaicin results in increased expression of IL1B protein]; Ranitidine inhibits the reaction [Indomethacin results in increased expression of IL1B mRNA]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of IL1B protein] |
CTD |
PMID:15265675 PMID:17698507 PMID:30580614 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Indomethacin results in increased expression of IL4 protein] |
CTD |
PMID:29523851 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of IL6 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of IL6 mRNA]; Pentoxifylline inhibits the reaction [Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; Ranitidine inhibits the reaction [Capsaicin results in increased expression of IL6 protein]; Ranitidine inhibits the reaction [Indomethacin results in increased expression of IL6 protein]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of IL6 protein] |
CTD |
PMID:15265675 PMID:16401727 PMID:16415329 PMID:17698507 PMID:28648817 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inhbe |
inhibin subunit beta E |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in decreased expression of INHBE mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 7:63,176,221...63,179,209
Ensembl chr 7:63,176,219...63,179,172
|
|
G |
Insig1 |
insulin induced gene 1 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Lipopolysaccharides results in decreased expression of INSIG1 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Insig2 |
insulin induced gene 2 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Lipopolysaccharides results in decreased expression of INSIG2 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr13:32,472,390...32,500,139
Ensembl chr13:32,473,742...32,494,923
|
|
G |
Irs2 |
insulin receptor substrate 2 |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of IRS2 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482
|
|
G |
Itpkc |
inositol-trisphosphate 3-kinase C |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of ITPKC mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 1:82,500,957...82,522,533
Ensembl chr 1:82,500,957...82,522,779
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of JUN mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Klf4 |
KLF transcription factor 4 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of KLF4 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of KLF4 mRNA] |
CTD |
PMID:16401727 PMID:16415329 |
|
NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
|
|
G |
Klf6 |
KLF transcription factor 6 |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of KLF6 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Rotenone results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:19723537 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Rotenone results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:19723537 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapkapk2 |
MAPK activated protein kinase 2 |
multiple interactions increases expression |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of MAPKAPK2 mRNA Ranitidine results in increased expression of MAPKAPK2 mRNA |
CTD |
PMID:16401727 PMID:16415329 |
|
NCBI chr13:42,513,762...42,560,061
Ensembl chr13:42,513,762...42,560,457
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Ethanol results in increased secretion of and results in increased activity of MMP9 protein]; Ranitidine inhibits the reaction [Indomethacin results in increased expression of MMP9 protein] |
CTD |
PMID:17603938 PMID:29523851 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions decreases expression |
EXP |
Ranitidine inhibits the reaction [Aspirin results in increased expression of MPO protein]; Ranitidine inhibits the reaction [Indomethacin results in increased activity of MPO protein] Ranitidine results in decreased expression of MPO protein |
CTD |
PMID:12023551 PMID:16169175 PMID:17895592 PMID:18726076 PMID:28648817 PMID:30885738 More...
|
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of MYC mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nedd4l |
NEDD4 like E3 ubiquitin protein ligase |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of NEDD4L mRNA |
CTD |
PMID:16415329 |
|
NCBI chr18:58,393,759...58,726,709
Ensembl chr18:58,393,509...58,723,137
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Indomethacin results in decreased expression of NFE2L2 mRNA] |
CTD |
PMID:28648817 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Capsaicin results in increased expression of NGF protein] |
CTD |
PMID:15265675 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Noct |
nocturnin |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of NOCT mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 2:135,271,189...135,291,407
Ensembl chr 2:135,271,189...135,291,400
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Indomethacin results in increased activity of NOS2 protein] |
CTD |
PMID:16169175 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Indomethacin results in decreased expression of NQO1 protein] |
CTD |
PMID:30580614 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of NR4A1 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of NUPR1 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 1:181,213,292...181,215,327
Ensembl chr 1:181,213,368...181,215,281
|
|
G |
P4ha1 |
prolyl 4-hydroxylase subunit alpha 1 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of P4HA1 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr20:27,302,046...27,352,098
Ensembl chr20:27,302,141...27,352,786
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein] |
CTD |
PMID:19723537 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pfkl |
phosphofructokinase, liver type |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of PFKL mRNA |
CTD |
PMID:16415329 |
|
NCBI chr20:10,664,285...10,686,324
Ensembl chr20:10,664,272...10,686,315
|
|
G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of PPP1R15A mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171
|
|
G |
Preb |
prolactin regulatory element binding |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Lipopolysaccharides results in increased expression of PREB mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 6:25,418,805...25,422,594
Ensembl chr 6:25,418,776...25,422,590
|
|
G |
Prl |
prolactin |
affects expression increases secretion |
ISO |
Ranitidine affects the expression of PRL protein Ranitidine results in increased secretion of PRL protein |
CTD |
PMID:7878608 PMID:9037573 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of PTGS2 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of PTGS2 mRNA]; Ranitidine inhibits the reaction [Indomethacin results in increased expression of PTGS2 mRNA]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] |
CTD |
PMID:16401727 PMID:16415329 PMID:29523851 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pvr |
PVR cell adhesion molecule |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of PVR mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 1:79,561,294...79,576,700
Ensembl chr 1:79,546,879...79,576,715
|
|
G |
Rac1 |
Rac family small GTPase 1 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of RAC1 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of RAC1 mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Indomethacin results in increased expression of RELA mRNA]; Ranitidine inhibits the reaction [Indomethacin results in increased expression of RELA protein] |
CTD |
PMID:28648817 PMID:30580614 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Ren |
renin |
affects activity |
ISO |
Ranitidine affects the activity of REN protein |
CTD |
PMID:1972605 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Rgs2 |
regulator of G-protein signaling 2 |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of RGS2 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385
|
|
G |
Rgs4 |
regulator of G-protein signaling 4 |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of RGS4 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr13:81,936,775...81,943,103
Ensembl chr13:81,936,775...81,943,068
|
|
G |
Rhob |
ras homolog family member B |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of ARHB mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of SERPINE1 mRNA; Heparin inhibits the reaction [Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of SERPINE1 protein]]; Pentoxifylline inhibits the reaction [Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of SERPINE1 protein]]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of SERPINE1 mRNA]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of SERPINE1 protein] |
CTD |
PMID:16401727 PMID:16415329 PMID:17698507 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sh2b2 |
SH2B adaptor protein 2 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of APS mRNA |
CTD |
PMID:16415329 |
|
NCBI chr12:20,427,057...20,456,845
Ensembl chr12:20,429,043...20,456,844
|
|
G |
Shank3 |
SH3 and multiple ankyrin repeat domains 3 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in decreased expression of SHANK3 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 7:120,568,707...120,630,796
Ensembl chr 7:120,570,402...120,630,374
|
|
G |
Sik1 |
salt-inducible kinase 1 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of SIK1 mRNA; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of SIK1 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr20:9,949,407...9,959,036
Ensembl chr20:9,947,396...9,958,991
|
|
G |
Slc16a6 |
solute carrier family 16, member 6 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of SLC16A6 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr10:94,424,377...94,447,482
Ensembl chr10:94,426,244...94,448,779
|
|
G |
Slc20a1 |
solute carrier family 20 member 1 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of SLC20A1 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 3:116,427,095...116,441,049
Ensembl chr 3:116,427,098...116,441,051
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions affects transport increases uptake |
ISO EXP |
Ranitidine inhibits the reaction [SLC22A1 protein results in increased transport of 1-Methyl-4-phenylpyridinium]; Ranitidine inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] SLC22A1 protein affects the transport of Ranitidine SLC22A1 protein results in increased uptake of Ranitidine |
CTD |
PMID:16006492 PMID:16141367 PMID:16263091 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
increases uptake multiple interactions |
ISO EXP |
SLC22A2 protein results in increased uptake of Ranitidine Ranitidine inhibits the reaction [SLC22A2 protein results in increased transport of 1-Methyl-4-phenylpyridinium]; Ranitidine inhibits the reaction [SLC22A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:16006492 PMID:16141367 PMID:16263091 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [SLC22A3 protein affects the transport of 1-Methyl-4-phenylpyridinium]; Ranitidine inhibits the reaction [SLC22A3 protein results in increased transport of 1-Methyl-4-phenylpyridinium]; Ranitidine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:16141367 PMID:16263091 |
|
NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612
|
|
G |
Slc22a6 |
solute carrier family 22 member 6 |
increases uptake |
ISO |
SLC22A6 protein results in increased uptake of Ranitidine |
CTD |
PMID:16006492 |
|
NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173
|
|
G |
Slc22a7 |
solute carrier family 22 member 7 |
increases uptake |
ISO |
SLC22A7 protein results in increased uptake of Ranitidine |
CTD |
PMID:16006492 |
|
NCBI chr 9:14,547,073...14,554,354
Ensembl chr 9:14,547,849...14,553,921
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
increases uptake multiple interactions |
ISO EXP |
SLC22A8 protein results in increased uptake of Ranitidine Penicillin G inhibits the reaction [SLC22A8 protein results in increased uptake of Ranitidine]; Probenecid promotes the reaction [SLC22A8 protein results in increased uptake of Ranitidine]; Ranitidine inhibits the reaction [SLC22A8 protein results in increased uptake of Cimetidine] |
CTD |
PMID:15319347 PMID:16006492 |
|
NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of SLC2A1 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slc38a2 |
solute carrier family 38, member 2 |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of SLC38A2 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 7:127,851,267...127,863,482
Ensembl chr 7:127,851,267...127,863,436
|
|
G |
Slc47a1 |
solute carrier family 47 member 1 |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:46,034,115...46,088,617
Ensembl chr10:46,034,122...46,087,637
|
|
G |
Slc47a2 |
solute carrier family 47 member 2 |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:45,990,806...46,033,937
Ensembl chr10:45,991,095...46,033,904
|
|
G |
Slc5a3 |
solute carrier family 5 member 3 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of SLC5A3 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of SLC5A3 mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr11:31,313,847...31,316,293
Ensembl chr11:31,295,476...31,318,883
|
|
G |
Slk |
STE20-like kinase |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of SLK mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of SLK mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr 1:246,473,712...246,529,643
Ensembl chr 1:246,473,712...246,526,530
|
|
G |
Sphk1 |
sphingosine kinase 1 |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of SPHK1 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr10:101,758,567...101,764,240
Ensembl chr10:101,758,711...101,764,240
|
|
G |
Tac1 |
tachykinin, precursor 1 |
increases expression |
ISO |
Ranitidine results in increased expression of TAC1 protein |
CTD |
PMID:12495560 |
|
NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178
|
|
G |
Tfrc |
transferrin receptor |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of TFRC mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of TFRC mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of TNF protein]]; Ranitidine inhibits the reaction [Histamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]] [IFNG protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Ranitidine; Ranitidine inhibits the reaction [Aspirin results in increased expression of TNF protein]; Ranitidine inhibits the reaction [Capsaicin results in increased expression of TNF protein]; Ranitidine inhibits the reaction [Indomethacin results in increased expression of TNF protein]; Ranitidine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:11752121 PMID:12023551 PMID:12538815 PMID:15265675 PMID:17698507 PMID:19362101 PMID:28648817 PMID:29523851 PMID:30885738 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of TNFAIP6 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649
|
|
G |
Tnfrsf12a |
TNF receptor superfamily member 12A |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of TNFRSF12A mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr10:12,707,077...12,709,071
Ensembl chr10:12,689,890...12,709,045
|
|
G |
Tpm3 |
tropomyosin 3 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of TPM3 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 2:175,517,198...175,545,014
Ensembl chr 2:175,517,226...175,545,013
|
|
G |
Trak2 |
trafficking kinesin protein 2 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of TRAK2 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 9:60,348,531...60,414,036
Ensembl chr 9:60,350,012...60,413,996
|
|
G |
Ube2b |
ubiquitin-conjugating enzyme E2B |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of UBE2B mRNA |
CTD |
PMID:16415329 |
|
NCBI chr10:36,248,434...36,263,379
Ensembl chr10:36,248,438...36,264,665
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of VEGFA mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Zbtb10 |
zinc finger and BTB domain containing 10 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ZBTB10 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 2:92,475,254...92,509,892
Ensembl chr 2:92,479,014...92,512,515
|
|
G |
Zfyve27 |
zinc finger FYVE-type containing 27 |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of ZFYVE27 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 1:240,979,831...241,003,193
Ensembl chr 1:240,979,842...241,003,193
|
|
|
G |
Fmo3 |
flavin containing dimethylaniline monoxygenase 3 |
affects metabolic processing increases metabolic processing multiple interactions increases oxidation |
ISO EXP |
FMO3 gene polymorphism affects the metabolism of trimethylamine FMO3 protein results in increased metabolism of trimethylamine trimethylamine inhibits the reaction [FMO3 protein results in increased oxidation of Methimazole] FMO3 protein results in increased oxidation of trimethylamine FMO3 protein results in increased oxidation of trimethylamine; FMO3 results in increased oxidation of trimethylamine |
CTD |
PMID:11414682 PMID:12214664 PMID:16601883 PMID:17050781 PMID:17142560 |
|
NCBI chr13:75,309,367...75,334,915
Ensembl chr13:75,309,374...75,328,028
|
|
G |
Mtarc1 |
mitochondrial amidoxime reducing component 1 |
multiple interactions increases chemical synthesis |
ISO |
[MTARC1 protein results in increased reduction of trimethyloxamine] which results in increased chemical synthesis of trimethylamine MTARC1 protein results in increased chemical synthesis of trimethylamine |
CTD |
PMID:29856598 |
|
NCBI chr13:96,324,377...96,362,677
Ensembl chr13:96,339,757...96,397,796
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
affects abundance |
ISO |
SLCO1A4 protein affects the abundance of trimethylamine |
CTD |
PMID:21561886 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Taar5 |
trace amine-associated receptor 5 |
increases activity |
ISO |
trimethylamine results in increased activity of TAAR5 protein |
CTD |
PMID:23393561 |
|
NCBI chr 1:21,469,923...21,470,936
Ensembl chr 1:21,469,923...21,470,936
|
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions |
ISO |
trimethyloxamine inhibits the reaction [Tobacco Smoke Pollution analog results in increased expression of ATF4 protein] |
CTD |
PMID:25568320 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
trimethyloxamine inhibits the reaction [Tobacco Smoke Pollution analog results in increased cleavage of CASP3 protein] |
CTD |
PMID:25568320 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
trimethyloxamine inhibits the reaction [Tobacco Smoke Pollution analog results in increased expression of DDIT3 protein] |
CTD |
PMID:25568320 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Mbp |
myelin basic protein |
multiple interactions |
ISO |
trimethyloxamine promotes the reaction [MBP protein binds to MBP protein]; trimethyloxamine promotes the reaction [MBP protein mutant form binds to MBP protein mutant form] |
CTD |
PMID:12372316 |
|
NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404
|
|
G |
Mtarc1 |
mitochondrial amidoxime reducing component 1 |
multiple interactions increases reduction |
ISO |
[MTARC1 protein results in increased reduction of trimethyloxamine] which results in increased chemical synthesis of trimethylamine; NAD affects the reaction [MTARC1 protein results in increased reduction of trimethyloxamine] |
CTD |
PMID:29856598 |
|
NCBI chr13:96,324,377...96,362,677
Ensembl chr13:96,339,757...96,397,796
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
affects abundance |
ISO |
SLCO1A4 protein affects the abundance of trimethyloxamine |
CTD |
PMID:21561886 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Vamp2 |
vesicle-associated membrane protein 2 |
multiple interactions |
EXP |
trimethyloxamine promotes the reaction [rimabotulinumtoxinB results in increased cleavage of VAMP2 protein modified form] |
CTD |
PMID:27032463 |
|
NCBI chr10:53,793,581...53,797,815
Ensembl chr10:53,793,923...53,797,809
|
|